Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.58 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6107968 | 0.89 | F10 (0.73) | F10F2 | |
| SCHEMBL6108762 | 0.86 | F10 (0.65) | F10F2 | |
| SCHEMBL6107514 | 0.86 | F10 (0.64) | F10F2FFAR2 | |
| SCHEMBL5758058 | 0.84 | KCNMA1 (0.55) | F10KCNMA1KDM4EGAAHPGD | |
| SCHEMBL5758733 | 0.84 | KDM4E (0.48) | F10KCNMA1KDM4EGAAHPGD | |
| SCHEMBL6107570 | 0.83 | F10 (0.60) | F10ALOX15F2TDP1 | |
| SCHEMBL6108954 | 0.83 | F10 (0.65) | F10TSHRF2 | |
| SCHEMBL6106469 | 0.82 | F10 (0.64) | F10TSHRF2 | |
| SCHEMBL6108134 | 0.81 | F10 (0.62) | F10 | |
| Hydrochloric Acid SCHEMBL6109850 | 0.81 | F10 (0.62) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140881-B1 | ANTITHROMBOTIC AMIDES | LILLY CO ELI (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6780878-B2 | ANTICOAGULANTS; CARDIOVASACULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-6716839-B2 | INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6716855-B2 | INHIBITOR OF FACTOR XA; N1-(BENZOYL)-N2-(1-(4-PYRIDYL)PIPERIDIN-4-YL-METHYL)-1,2-BENZENDIAMINE HIGH BIOAVAILABILITY | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6710057-B2 | INHIBITORS OF FACTOR XA, AS ANTICOAGULANTS FOR PROPHYLAXIS AND TREATMENT OF THROMBOEMBOLIC DISORDERS | ELI LILLY AND COMPANY | 2004-03-23 | — | — | US | disclosed |
| US-20030212069-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-11-13 | — | — | US | disclosed |
| US-20030199504-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030199505-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030191153-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-09 | — | — | US | disclosed |
| US-6610704-B1 | Inhibit factor Xa | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191153-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | F10 13/4885KCNMA1 1137/4885KDM4E 2930/4885 |
| US-20030199504-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | F10 13/4885KCNMA1 1137/4885KDM4E 2930/4885 |
| US-20030212069-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | F10 13/4885KCNMA1 1137/4885KDM4E 2930/4885 |
| US-20030199505-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | F10 13/4885KCNMA1 1137/4885KDM4E 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.